| Literature DB >> 14739938 |
Matthias Kappler1, Matthias Bache, Frank Bartel, Matthias Kotzsch, Matti Panian, Peter Würl, Karen Blümke, Hannelore Schmidt, Axel Meye, Helge Taubert.
Abstract
Survivin, a member of the inhibitors-of-apoptosis gene family, is overexpressed in many tumor types. Survivin is a prognostic marker of soft-tissue sarcomas, but the downregulation of survivin expression and the possible dependency of survivin downregulation on p53 in these tumors have not been investigated. Therefore, we applied small interfering RNA (siRNA) to knock down the expression of survivin in five human sarcoma cell lines with wild-type or mutant p53 alleles. Compared with survivin mRNA expression in the nonsense siRNA-treated sarcoma cell lines, expression after treatment with survivin-specific siRNA was reduced by 73-88%; survivin protein expression was reduced by 52-81%. This finding was coupled with a reduction in clonogenic survival ranging from 65-86%. However, less than 10% of cells treated with survivin-specific siRNA underwent apoptosis. Cell-cycle and morphologic analyses showed that after a dramatic increase in the number of treated cells in the G2/M phase, some of the cells became polyploid; this result indicates that mitosis of a substantial number of treated cells was incomplete. Our findings suggest that survivin-specific siRNA could be a selective treatment to kill sarcoma cells regardless of the presence or absence of wild-type p53 alleles.Entities:
Mesh:
Substances:
Year: 2004 PMID: 14739938 DOI: 10.1038/sj.cgt.7700677
Source DB: PubMed Journal: Cancer Gene Ther ISSN: 0929-1903 Impact factor: 5.987